IP Verse

Topical Localized Isoxazoline Formulation Comprising Glycofurol - EP2658541

The patent EP2658541 was granted to Intervet on Jan 26, 2022. The application was originally filed on Dec 22, 2011 under application number EP11799292A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2658541

INTERVET
Application Number
EP11799292A
Filing Date
Dec 22, 2011
Status
Granted And Under Opposition
Dec 24, 2021
Grant Date
Jan 26, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

VIRBACOct 25, 2022GEVERS & ORESADMISSIBLE

Patent Citations (29) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2007066617
DESCRIPTIONUS3950360
DESCRIPTIONUS3984564
DESCRIPTIONUS4916154
DESCRIPTIONUS5288710
DESCRIPTIONUS5399717
DESCRIPTIONWO2007079162
DESCRIPTIONWO2009002809
DESCRIPTIONWO2009003075
DESCRIPTIONWO2009024541
DESCRIPTIONWO2010070068
DESCRIPTIONWO2010079077
DESCRIPTIONWO2011075591
EXAMINATIONWO2011157733
INTERNATIONAL-SEARCH-REPORTUS2010311685
INTERNATIONAL-SEARCH-REPORTWO2009024541
OPPOSITIONUS2007066617
OPPOSITIONUS2010311685
OPPOSITIONWO2005105101
OPPOSITIONWO2007018659
OPPOSITIONWO2007079162
OPPOSITIONWO2009002809
OPPOSITIONWO2009003075
OPPOSITIONWO2009024541
OPPOSITIONWO2010070068
OPPOSITIONWO2010079077
OPPOSITIONWO2010128095
OPPOSITIONWO2011075591
OPPOSITIONWO2018039508

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Barakat Nahla Salah, "Evaluation of Glycofurol-Based Gel as a New Vehicle for Topical Application of Naproxen", AAPS PharmSciTech, (20100903), vol. 11, no. 3, pages 1138 - 1146, XP055977227-
OPPOSITION- Bravecto® Spot-on (Marketing Authorization-
OPPOSITION- Rowe (ed.), Et Al, "Glycofurol", Rowe (ed.), Et Al, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090101), pages 297 - 298, ISBN 978-0-85369-792-3, XP055977222-
OPPOSITION- Rufener Lucien, Et Al, "The novel isoxazoline ectoparasiticidelotilaner (Credelio™): a non-competitive antagonist specific to invertebrates y-aminobutyric acid-gated chloride channels (GABACIs)", Parasites & Vectors, (20170101), vol. 10, no. 530, pages 1 - 15, XP055977350-
OPPOSITION- Taenzler Janina, Et Al, "Efficacy of fluralaner spot-on solution against induced infestations with Rhipicephalus sanguineus on dogs", Parasites & Vectors, (20160101), vol. 9, no. 276, pages 1 - 5, XP055977232-
OPPOSITION- Xu Ming, Et Al, "13 The Discovery of Afoxolaner: A New Ectoparasiticide for Dogs", Ectoparasites - Drug discovery against moving targets, Wiley VCH, (20180101), pages 259 - 271, ISBN 978-3-527-34168-9, XP055977348-
OPPOSITION- Ozoe, Y. et al, "The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels", Biochemical and Biophysical Research Communications, Amsterdam NL , (20100101), vol. 391, no. 1, doi:10.1016/j.bbrc.2009.11.131, ISSN 0006-291X, pages 744 - 749, XP026823770

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents